- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04142996
Comparing Uni- and Bi-lateral TBS in Major Depression
A Naturalistic Study Comparing Uni- and Bi-lateral Theta Burst Stimulation in Major Depression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily session delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm which reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. However, it remains to be determined if applying TBS to both sides of the frontal cortex (i.e. bilateral TBS) is more efficient than delivering it to only one side (i.e. unilateral TBS). In addition, it is difficult to predict treatment response as there is a lack of tools to identify potential responders early on in the treatment phase. Finally, the effects of rTMS are known to last up to 12 months after the treatment. To avoid relapse, a maintenance phase is typically introduced after treatment in which treatment sessions are delivered at a gradually decreasing rate. This study proposes to bridge these gaps by conducting a randomized double-blinded naturalistic superiority trial in which the efficacy of bilateral and unilateral TBS will be compared in individuals with a diagnosis of major depressive episodes. Neurobiological markers of response will be assessed at different time points. In people that respond to treatment, a 6-month maintenance phase will be conducted using a flexible schedule.
The study has four primary aims:
- To compare the efficacy of bilateral and unilateral TBS on symptoms of depression, as well as rates of remission and response
- To investigate how unilateral and bilateral TBS modulates brain activity in the dorsolateral prefrontal cortex (DLPFC) using interleaved TMS-EEG
- To investigate neural predictors of the clinical response to TBS.
- To assess the efficacy of a flexible schedule of maintenance on a period of 6 months on symptoms of depression and rate of relapse.
TREATMENT PHASE TBS treatment will be administered 5 days/week (on weekdays) over a first phase of 4 weeks (20 sessions). If remission is achieved (Hamilton Rating Scale for Depression-17 score < 8), treatment will cease and the patient will move on to the maintenance phase. Non-remitters will receive a second phase of treatment, consisting of an additional 2 weeks (10 sessions, for a total of 30). After 6 weeks, all responders may move on to the maintenance phase.
MAINTENANCE PHASE The maintenance phase will be of 6 months duration from the end of the randomized treatment. For each TBS condition, responders will be assigned to a flexible maintenance protocol based on symptom emergence. Participants will receive a fixed 2x/week schedule for the month 1. For month 2 and 3, a brief weekly assessment (Hamilton Rating Scale for Depression-17 score) will be conducted in which it will be determined if they will receive 0, 1 or 2 sessions in the week. For month 4 and 5, a bimonthly assessment (Hamilton Rating Scale for Depression-17 score) will be conducted in which it will be determined if they will receive 0, 1 or 2 sessions over the two weeks. For month 6, one brief assessment (Hamilton Rating Scale for Depression-17 score) will be conducted in which it will be determined if they will receive 0, 1 or 2 sessions in the month.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stacey Shim, MSc
- Phone Number: 6356 613-722-6521
- Email: stacey.shim@theroyal.ca
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Z 7K4
- Recruiting
- The Royal Ottawa Mental Health Centre
-
Contact:
- Sara Tremblay
- Phone Number: 6227 613-722-6521
- Email: Sara.Tremblay@theroyal.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- voluntary and competent to consent to study,
- female or male aged 18 years old or older,
- can speak and read English and/or French
- primary and/or predominant diagnosis of major depressive episode without psychotic features in the current depressive episode (confirmed by a Mini-International Neuropsychiatric Interview),
- depressive symptoms have not improved after ≥ 1 adequate dose of antidepressant trial in the current depressive episode,
- moderate symptoms in the current depressive episode as indexed by a score of at least 15 at the 17-item Hamilton Rating Scale for Depression (HRSD-17),
- have been referred to rTMS treatment by their treating physician, and took a free and informed decision to follow this treatment,
- are able to adhere to treatment schedule,
- have received a stable psychiatric medication (including prescribed cannabis) or psychotherapy regimen for at least four weeks prior to entering the trial,
- have an education-adjusted score of ≥ 24 at the Mini-Mental State Evaluation (MMSE) if are aged ≥ 65.
Exclusion Criteria:
- current or past (< 3 months) substance (excluding caffeine or nicotine) or alcohol abuse/dependence, as defined in the Diagnostic and Statistical Manual 5th Edition (DSM-5) criteria. Based on the DSM-5 criteria, mild cannabis or alcohol use would be permissible in the past 3 months, moderate to severe would be an exclusion
- current use of illegal substances or recreational cannabis
- have a concomitant major unstable medical or neurologic illness (e.g. uncontrolled diabetes or renal dysfunction),
- organic cause to the depressive symptoms (e.g. thyroid dysfunctions), determined by the referring physician
- acute suicidality or threat to life from self-neglect,
- are pregnant or breastfeeding, or thinking of becoming pregnant during course of treatment,
- have a specific contraindication for TMS (e.g., personal history of epilepsy or seizure, metallic head implant, pacemaker),
- unwilling to maintain current antidepressant regimen,
- are taking more than 1 mg of lorazepam or equivalent,
- any other condition that, in the opinion of the investigators, would adversely affect the participant's ability to complete the study,
- have failed a course of electroconvulsive therapy (ECT) within the current depressive episode due to the lower likelihood of response to rTMS.If they have had failed ECT in the past, this does not exclude them
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Unilateral TBS
Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC.
Realistic sham continuous TBS (cTBS-sham) will be applied to the right DLPFC.
Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
|
Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
|
Active Comparator: Bilateral TBS
Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC and continuous TBS (cTBS) will be applied to the right DLPFC.
Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
|
Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
|
Active Comparator: Maintenance Phase: Flexible
The flexible maintenance protocol will be based on symptom emergence.
Participants will receive a fixed TBS (2x/week) schedule for the first month.
For the following months (2-6), they will come in for an assessment (HRSD-17) to determine how many TBS sessions (0, 1, or 2) they receive on a flexible basis.
|
Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response - Treatment Phase (Hamilton Rating Scale for Depression-17 score)
Time Frame: Week 6
|
Response to treatment will be defined as a > 50% reduction in pre-treatment symptoms severity as measured by the mean Hamilton Rating Scale for Depression-17 score.
The minimum value is 0 and the maximum value is 53.
A higher score indicates a negative outcome.
|
Week 6
|
Remission - Treatment Phase (Hamilton Rating Scale for Depression-17 Score)
Time Frame: End of treatment phase (week 4 or 6)
|
Remission will be defined as a Hamilton Rating Scale for Depression-17 score ≤ 8 The minimum value is 0 and the maximum value is 53.
A higher score indicates a negative outcome.
|
End of treatment phase (week 4 or 6)
|
Response - Maintenance Phase (Hamilton Rating Scale for Depression-17 score)
Time Frame: 6 months
|
Response to treatment will be defined as a > 50% reduction in pre-treatment symptoms severity as measured by the mean Hamilton Rating Scale for Depression-17 score.
The minimum value is 0 and the maximum value is 53.
A higher score indicates a negative outcome
|
6 months
|
Remission - Maintenance Phase (Hamilton Rating Scale for Depression-17 Score)
Time Frame: 6 months
|
Remission will be defined as a Hamilton Rating Scale for Depression-17 score ≤ 8 The minimum value is 0 and the maximum value is 53.
A higher score indicates a negative outcome.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response - Treatment Phase (Quick Inventory of Depression Symptomology-Self Report)
Time Frame: Week 6
|
Response to treatment will be defined as a > 50% reduction in pre-treatment symptoms severity as measured by the mean the Quick Inventory of Depression Symptomology-Self Report score.
The minimum value is 0 and the maximum value is 48.
A higher score indicates a negative outcome.
|
Week 6
|
Remission - Treatment Phase (Quick Inventory of Depression Symptomology-Self Report)
Time Frame: End of treatment phase (week 4 or 6)
|
Remission will be defined as a Quick Inventory of Depression Symptomology-Self Report score ≤ 6.
The minimum value is 0 and the maximum value is 48.
A higher score indicates a negative outcome
|
End of treatment phase (week 4 or 6)
|
Response - Maintenance Phase (Quick Inventory of Depression Symptomology-Self Report)
Time Frame: 6 months
|
Response to treatment will be defined as a > 50% reduction in pre-treatment symptoms severity as measured by the mean the Quick Inventory of Depression Symptomology-Self Report score.
The minimum value is 0 and the maximum value is 48.
A higher score indicates a negative outcome.
|
6 months
|
Remission - Maintenance Phase Quick Inventory of Depression Symptomology-Self Report)
Time Frame: 6 months
|
Remission will be defined as a Quick Inventory of Depression Symptomology-Self Report score ≤ 6.
The minimum value is 0 and the maximum value is 48.
A higher score indicates a negative outcome.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cortical Activity - Treatment Phase
Time Frame: Week 6
|
TMS-EEG measure of cortical activity (change in pre-treatment TMS-evoked potential amplitude in µV).
|
Week 6
|
Cortical Activity - Maintenance Phase
Time Frame: 6 months
|
TMS-EEG measure of cortical activity (change in pre-treatment TMS-evoked potential amplitude in µV).
|
6 months
|
Resting State Connectivity
Time Frame: 6 months
|
Investigate if baseline levels of GABA/Glutamate in the anterior cingulate cortex (ACC) and baseline levels of resting state connectivity between the left dorsolateral prefrontal.
cortex (DLPFC) and ACC are linked to therapeutic response, using resting state functional Connectivity between target sites and anterior cingulate cortex (ACC)
|
6 months
|
Magnetic Resonance Spectroscopy
Time Frame: 6 months
|
Baseline levels of gamma-aminobutyric acid (GABA) and Glutamate in the anterior cingulate cortex (ACC)
|
6 months
|
Cortical Activity in Motor Cortex
Time Frame: 6 months
|
Baseline levels excitation and inhibition measured with Transcranial Magnetic Stimulation
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sara Tremblay, PhD, The Royal Ottawa Mental Health Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Episode
-
University Hospital, MontpellierRecruitingMajor Depressive EpisodeFrance
-
Medical University of ViennaUnknownMajor Depressive EpisodeAustria
-
The University of New South WalesWesley MissionUnknown
-
Northside Clinic, AustraliaWesley MissionCompletedMajor Depressive EpisodeAustralia
-
Jiangsu Province Nanjing Brain HospitalRecruitingMajor Depressive EpisodeChina
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
University of British ColumbiaRecruitingMajor Depressive Disorder | Major Depressive EpisodeCanada
-
Weill Medical College of Cornell UniversityUnknownMajor Depressive Disorder | Major Depressive EpisodeUnited States
-
Institut National de la Santé Et de la Recherche...CompletedMajor Depressive Disorder | Major Depressive EpisodeFrance
Clinical Trials on Theta burst stimulation
-
Erika ForbesNational Institute of Mental Health (NIMH)Completed
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoRecruiting
-
Nicholas Balderston, PhDRecruiting
-
University of California, Los AngelesNational Institute on Aging (NIA)RecruitingCognitive Dysfunction | Memory Disorders in Old AgeUnited States
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruiting
-
Chang Gung Memorial HospitalCompletedCerebral Vascular AccidentTaiwan
-
Changping LaboratoryNot yet recruitingAphasia | Stroke, Ischemic
-
University of California, San DiegoUniversity of Pennsylvania; Milken InstituteActive, not recruiting
-
Sunnybrook Health Sciences CentreRecruitingPost Concussion SyndromeCanada
-
Changping LaboratoryRecruiting